Drug Approval | February 19, 2022
US FDA to review Amylyx new drug application for AMX0035
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
The injunction order has been passed against Natco Pharma, Torrent Pharmaceuticals, Eris Lifesciences and Windlas Biotech
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
Packaged junk food which is a major component of unhealthy diets is responsible for more deaths worldwide than any other risk factor
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace
Subscribe To Our Newsletter & Stay Updated
